Search results for "path"

showing 10 items of 15327 documents

NOTCH signalling in ovarian cancer angiogenesis

2020

The Notch signalling pathway is involved in the new vessel formation process by regulating tip and stalk cells, which are key cells in the sprout formation. This process is essential in both normal ovary and cancer angiogenesis and is regulated by Notch-VEGF crosstalk. Furthermore, Notch has been linked in ovary with stem cell maintenance and epithelial mesenchymal transition processes. Dysregulation of the Notch pathway is frequent in ovarian cancer (OC) and it has been associated with impaired survival and advanced stages or lymph node involvement. Notch also plays a role in chemoresistance to platinum. In this context, this pathway has emerged as an attractive target for precision medici…

0301 basic medicineDemcizumabAngiogenesisNotch signaling pathway610 Medicine & healthContext (language use)General MedicineBiologymedicine.disease10174 Clinic for Gynecology03 medical and health sciencesReview Article on Ovarian Cancer: State of the Art and Perspectives of Clinical Research030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesismedicineCancer researchEpithelial–mesenchymal transitionStem cellOvarian cancerGamma secretaseAnnals of Translational Medicine
researchProduct

AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

2017

Abstract This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (…

0301 basic medicineDiagnostic ImagingLiver Cirrhosismedicine.medical_specialtyCirrhosisEpidemiologySettore MED/12 - GASTROENTEROLOGIAPhysiopathologyNatural historyType 2 diabetesDiseaseDiagnosis; Epidemiology; Genetics; Management; Natural history; PhysiopathologyBioinformaticsGastroenterology03 medical and health sciences0302 clinical medicineGeneticNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseDiagnosismedicineGeneticsHumansmedicine.diagnostic_testHepatologyDiagnosis; Epidemiology; Genetics; Management; Natural history; Physiopathology; Hepatology; Gastroenterologybusiness.industryLiver NeoplasmsGastroenterologyHepatologymedicine.diseaseManagement030104 developmental biologyLipotoxicityDiabetes Mellitus Type 2LiverCardiovascular DiseasesLiver biopsy030211 gastroenterology & hepatologySteatohepatitisbusinessBiomarkersDiagnosi
researchProduct

Circadian rhythms in the pathogenesis of gastrointestinal diseases

2018

The etiology of digestive pathologies such as irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) and cancer is not yet fully understood. In recent years, several studies have evidenced circadian variations in mechanisms involved in digestive health. In situations of disturbed circadian rhythms (chronodisruption) where the central clock and the peripheral clocks receive incoherent signals, the synchronicity is lost producing implications for health. This lack of coordination could alter the tissue function and cause long term damage to the organs. Life habits such as sleep, physical exercise, social interaction, and feeding times are determinants for stability and integrity of…

0301 basic medicineDigestive cancersGastrointestinal DiseasesPhysical exerciseBioinformaticsInflammatory bowel diseaseInflammatory bowel diseasePathogenesis03 medical and health sciencesCircadian ClocksmedicineHumansCircadian rhythmsCircadian rhythmHealthy LifestyleDigestive cancerIrritable bowel syndromebusiness.industryGastroenterologyLong term damageGeneral Medicinemedicine.diseaseCircadian RhythmGastrointestinal TractIrritable bowel syndrome030104 developmental biologyEditorialEtiologybusinessWorld Journal of Gastroenterology
researchProduct

Gut Microbiota and Risk of Developing Celiac Disease

2016

Gut microbiota shapes the development of the mucosal immune system and may provide protection against immune-mediated diseases. Celiac disease (CD) is a chronic inflammatory condition triggered by dietary gluten proteins, recently associated with gut microbiota alterations in cross-sectional studies comparing patients and controls. Whether or not these differences are causally related to the disease has yet to be elucidated, but evaluation of specific bacteria isolated from CD patients in experimental models suggests that they can promote an adverse response to dietary gluten, whereas other commensal bacteria can be protective. Genetic and environmental factors associated with increased CD …

0301 basic medicineDiseaseEnvironmentGut floradigestive systemEpigenesis GeneticPathogenesis03 medical and health sciences0302 clinical medicineImmune systemRisk FactorsHumansMedicineEpigeneticsEpigenesischemistry.chemical_classificationbiologybusiness.industryGastroenterologyInfantbiology.organism_classificationCommensalismGlutenGastrointestinal MicrobiomeCeliac Disease030104 developmental biologychemistryImmunology030211 gastroenterology & hepatologybusinessJournal of Clinical Gastroenterology
researchProduct

SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprote…

2019

Objective: Abdominal aortic aneurysm (AAA) is a pathological condition of permanent vessel dilatation that predisposes to the potentially fatal consequence of aortic rupture. SGLT-2 (sodium-glucose cotransporter 2) inhibitors have emerged as powerful pharmacological tools for type 2 diabetes mellitus treatment. Beyond their glucose-lowering effects, recent studies have shown that SGLT-2 inhibitors reduce cardiovascular events and have beneficial effects on several vascular diseases such as atherosclerosis; however, the potential effects of SGLT-2 inhibition on AAA remain unknown. This study evaluates the effect of oral chronic treatment with empagliflozin—an SGLT-2 inhibitor—on dissecting …

0301 basic medicineDissecting Abdominal Aortic AneurysmApolipoprotein EMalemedicine.medical_specialtyInflammation030204 cardiovascular system & hematologyp38 Mitogen-Activated Protein Kinases03 medical and health sciencesMice0302 clinical medicineApolipoproteins EGlucosidesInternal medicinemedicineAnimalsHumansBenzhydryl CompoundsAortic ruptureSodium-Glucose Transporter 2 InhibitorsCells CulturedNeovascularization Pathologicbusiness.industryAngiotensin IINF-kappa Bmedicine.diseaseAngiotensin IIAbdominal aortic aneurysmMatrix MetalloproteinasesMice Inbred C57BLAortic Dissection030104 developmental biologyEndocrinologySodium/Glucose Cotransporter 2Knockout mousemedicine.symptomChemokinesCardiology and Cardiovascular MedicinebusinessAortic Aneurysm AbdominalArteriosclerosis, thrombosis, and vascular biology
researchProduct

Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by in Silico and in Vitro Analyses

2018

Drug resistance is one of the main reasons of chemotherapy failure. Therefore, overcoming drug resistance is an invaluable approach to identify novel anticancer drugs that have the potential to bypass or overcome resistance to established drugs and to substantially increase life span of cancer patients for effective chemotherapy. Oridonin is a cytotoxic diterpenoid isolated from Rabdosia rubescens with in vivo anticancer activity. In the present study, we evaluated the cytotoxicity of oridonin toward a panel of drug-resistant cancer cells overexpressing ABCB1, ABCG2, or ΔEGFR or with a knockout deletion of TP53. Interestingly, oridonin revealed lower degree of resistance than the control dr…

0301 basic medicineDrug resistancenatural compound03 medical and health sciences0302 clinical medicineIn vivomedicinePharmacology (medical)DoxorubicinProtein kinase BPI3K/AKT/mTOR pathwayOriginal ResearchPharmacologydrug resistanceChemistrylcsh:RM1-950molecular dockingmolecular dynamics030104 developmental biologylcsh:Therapeutics. PharmacologyDocking (molecular)030220 oncology & carcinogenesisPharmacogenomicsCancer cellCancer researchmicroarraymedicine.drugcluster analysisFrontiers in Pharmacology
researchProduct

Plant polyphenols, chemoreception, taste receptors and taste management

2019

International audience; Purpose of review Polyphenols display beneficial health effects through chemopreventive actions on numerous chronic diseases including cancers, metabolic disorders, reproductive disorders and eating behaviour disorders. According to the principle of chemoreception, polyphenols bind cellular targets capable of accepting their stereochemistry, namely metabolizing enzymes and protein receptors, including taste receptors. The extraoral expression of taste receptors and their pharmacological interest in terms of novel drug therapies open up new perspectives on the potential use of these compounds and their interactions with other chemicals in cells. These new perspectives…

0301 basic medicineDrugTasteChemoreceptormedia_common.quotation_subjectPhytochemicalsMedicine (miscellaneous)BiologyPharmacologybitterness03 medical and health sciences0302 clinical medicineTaste receptortanninsHumansReceptorEating behaviourmedia_common030109 nutrition & dieteticsNutrition and DieteticsPolyphenolsfood and beverages030208 emergency & critical care medicineTaste Budstype 2 taste receptor modulationtaste interaction3. Good healthPolyphenolTaste(iso)flavonoidsSignalling pathways[SDV.AEN]Life Sciences [q-bio]/Food and NutritionSignal Transduction
researchProduct

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct

Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

2021

The molecular pathways which promote lung cancer cell features have been broadly explored, leading to significant improvement in prognostic and diagnostic strategies. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have dramatically altered the treatment approach for patients with metastatic non-small cell lung cancer (NSCLC). Latest investigations by using next-generation sequencing (NGS) have shown that other oncogenic driver mutations, believed mutually exclusive for decades, could coexist in EGFR-mutated NSCLC patients. However, the exact clinical and pathological role of concomitant genomic aberrations needs to be investigated. In this systematic review, we ai…

0301 basic medicineEGFRNSCLC03 medical and health sciences0302 clinical medicinesystematic reviewPathologyRB1-214MedicineEpidermal growth factor receptorLung cancerPathologicalbiologybusiness.industrymedicine.diseaserespiratory tract diseasesconcurrent genomic alterationCritical appraisal030104 developmental biologyLung cancer cellconcurrent genomic alterationsNGS030220 oncology & carcinogenesisConcomitantCancer researchbiology.proteinNon small cellbusinessTyrosine kinase<i>EGFR</i>Journal of Molecular Pathology
researchProduct